ZA94568B - G-CSF analog compositions and methods - Google Patents

G-CSF analog compositions and methods

Info

Publication number
ZA94568B
ZA94568B ZA94568A ZA94568A ZA94568B ZA 94568 B ZA94568 B ZA 94568B ZA 94568 A ZA94568 A ZA 94568A ZA 94568 A ZA94568 A ZA 94568A ZA 94568 B ZA94568 B ZA 94568B
Authority
ZA
South Africa
Prior art keywords
analogs
csf
methods
another aspect
compositions
Prior art date
Application number
ZA94568A
Other languages
English (en)
Inventor
Timothy Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA94568(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA94568B publication Critical patent/ZA94568B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
ZA94568A 1993-01-28 1994-01-27 G-CSF analog compositions and methods ZA94568B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs

Publications (1)

Publication Number Publication Date
ZA94568B true ZA94568B (en) 1994-09-12

Family

ID=21743861

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA94568A ZA94568B (en) 1993-01-28 1994-01-27 G-CSF analog compositions and methods

Country Status (22)

Country Link
US (6) US5581476A (fi)
EP (8) EP0890640A3 (fi)
JP (7) JPH08506018A (fi)
KR (2) KR100375274B1 (fi)
CN (3) CN1118572C (fi)
AT (2) ATE195552T1 (fi)
AU (2) AU697451B2 (fi)
CA (4) CA2711007C (fi)
DE (1) DE69425516T2 (fi)
DK (3) DK2345724T3 (fi)
ES (3) ES2150951T3 (fi)
FI (2) FI120769B (fi)
GR (1) GR3034745T3 (fi)
HK (2) HK1009288A1 (fi)
IL (6) IL145994A (fi)
LU (1) LU92265I2 (fi)
LV (1) LV12642B (fi)
NO (3) NO952974L (fi)
NZ (5) NZ261765A (fi)
PT (3) PT2345724E (fi)
WO (1) WO1994017185A1 (fi)
ZA (1) ZA94568B (fi)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
CA2006596C (en) * 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
CA2244228A1 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) * 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
NZ507782A (en) * 1998-04-30 2003-12-19 Tanox Inc G-CSF receptor agonist antibodies and screening method therefor
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
CA2357811A1 (en) 1999-01-06 2000-07-13 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EA004685B1 (ru) * 1999-01-29 2004-06-24 Эмджен Инк. Конъюгаты гксф
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US20020164812A1 (en) * 1999-04-06 2002-11-07 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
WO2000060345A1 (en) * 1999-04-06 2000-10-12 University Of Alabama At Birmingham Research Foundation Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
CA2372526A1 (en) * 1999-05-10 2000-11-16 Michael D. Wyrsta Methods and compositions for controlled polypeptide synthesis
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP2003519478A (ja) * 2000-01-10 2003-06-24 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
EP1043239B1 (en) * 2000-06-16 2004-02-04 VSI Holding A/S Container with collapsible sides
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
WO2002018604A2 (en) * 2000-08-30 2002-03-07 The Salk Institute For Biological Studies Methods and compositions for determining isomerase enzymatic activity
US20040254351A1 (en) * 2000-09-07 2004-12-16 Beals John Michael Hyperglycosylated polypeptides
MXPA03002046A (es) * 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
AU2002212108A1 (en) * 2000-11-02 2002-05-15 Maxygen Aps Single-chain multimeric polypeptides
WO2002073373A2 (en) * 2001-03-12 2002-09-19 Board Of Regents, University Of Texas System Ensemble-based strategy for the design of protein pharmaceuticals
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
CA2452582C (en) * 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20040002108A1 (en) * 2002-05-23 2004-01-01 Vince Hilser Predicting the significance of single nucleotide polymorphisms (SNPs) using ensemble-based structural energetics
US20040007672A1 (en) * 2002-07-10 2004-01-15 Delucas Lawrence J. Method for distinguishing between biomolecule and non-biomolecule crystals
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
CA2496317C (en) * 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003273413A1 (en) * 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
EA008866B1 (ru) * 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
EP2140875A1 (en) * 2003-10-24 2010-01-06 Nora, LLC Compositions and methods for healthy pregnancy
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
AR048918A1 (es) * 2004-03-11 2006-06-14 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxietilo y eritropoyetina
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
WO2006055260A2 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
US7741096B2 (en) * 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
US7790174B2 (en) 2004-12-23 2010-09-07 Merck Serono Sa G-CSF polypeptides and uses thereof
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
KR100657749B1 (ko) * 2005-04-13 2006-12-20 씨제이 주식회사 인간 과립구 콜로니 형성인자 동종체 및 그 조성물
AU2006254543A1 (en) 2005-06-01 2006-12-07 Maxygen Holdings Ltd. PEGylated G-CSF polypeptides and methods of producing same
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN101243032B (zh) * 2005-08-15 2012-10-10 法雷斯药品研究公司 虾青素的晶型
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
US8129345B2 (en) * 2006-07-20 2012-03-06 Dana-Farber Cancer Institute, Inc. MUC1-IκB kinase complexes and their activities
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
JP4375412B2 (ja) * 2007-02-19 2009-12-02 株式会社デンソー 蒸発器ユニット
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2142651B1 (en) 2007-04-27 2013-05-22 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN101815944A (zh) * 2007-07-03 2010-08-25 安姆根有限公司 利用包含体干重的蛋白测量
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
WO2009103199A1 (zh) 2008-02-18 2009-08-27 江苏恒瑞医药股份有限公司 水溶性聚合物修饰的g-csf偶联物
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
AU2009274022B2 (en) 2008-07-22 2016-06-02 Menogenix, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
EP3225248B1 (en) * 2008-07-23 2023-06-07 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
CN102245632B (zh) 2008-10-17 2018-10-12 达娜-法勃肿瘤研究所公司 Muc-1胞质结构域肽作为癌症的抑制剂
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
TWI560197B (en) 2009-05-05 2016-12-01 Amgen Inc Fgf21 mutants and uses thereof
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010148142A1 (en) * 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CA2782814A1 (en) 2009-12-02 2011-06-09 Amgen Inc. Binding proteins that bind to human fgfr1c, human .beta.-klotho and both human fgfr1c and human .beta.-klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
CA2793586A1 (en) 2010-03-23 2011-09-29 Imba - Institut Fuer Molekulare Biotechnologie Gmbh Methods for identifying inhibitors of the type iii secretion system
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
DK3241558T3 (da) 2010-09-28 2021-04-26 Aegerion Pharmaceuticals Inc Højopløselige leptiner
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
US9993522B2 (en) 2012-09-18 2018-06-12 Uti Limited Partnership Treatment of pain by inhibition of USP5 de-ubiquitinase
RU2711091C2 (ru) 2013-03-15 2020-01-15 Гладиатор Байосайенсиз, Инк. Gla домены в качестве нацеливающих агентов
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
CN107949565A (zh) * 2015-06-11 2018-04-20 安姆生物制药有限责任公司 聚乙二醇化粒细胞集落刺激因子(gcsf)
EP3365360A1 (en) * 2015-10-19 2018-08-29 Sandoz AG Improved coding sequence for human g-csf
JP2020533976A (ja) 2017-09-05 2020-11-26 グラディエーター バイオサイエンシーズ インコーポレイテッド エキソソームを標的化する方法
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
BR112022006784A2 (pt) * 2019-10-08 2022-09-06 Zymeworks Inc Domínio extracelular modificado de receptor de fator estimulante de colônia de granulócito (g-csfr) e citocinas que se ligam ao mesmo
AU2020406137A1 (en) 2019-12-17 2022-06-16 Eberhard Karls Universität Tübingen Novel G-CSF mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0344796B1 (en) * 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
AU666866B2 (en) * 1991-08-30 1996-02-29 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) * 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
EP0668914B1 (en) * 1992-06-09 2000-08-16 Chiron Corporation Crystallization of m-csf
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
ES2211875T3 (es) 1992-11-24 2004-07-16 G.D. SEARLE & CO. Polipeptidos mutantes de interleuquina 3 (il-3).
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH11500308A (ja) 1995-02-03 1999-01-12 ジー．ディー．サール アンド カンパニー 新規ｃ−ＭＰＬリガンド
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
EP0859843A1 (en) 1995-10-05 1998-08-26 G.D. Searle & Co. Novel g-csf receptor agonists
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CA2234059A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel c-mpl receptor agonists
NZ320978A (en) 1995-10-05 2001-03-30 G Hematopoietic proteins and nucleic acid sequences encoding them
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
RU2245887C2 (ru) 1996-10-25 2005-02-10 Джи. Ди. Сирл Энд Ко. Гемопоэтический белок (варианты), последовательность днк, способ получения гемопоэтического белка, способ селективной экспансии кроветворных клеток, способ продуцирования дендритных клеток, способ стимуляции продуцирования кроветворных клеток у пациента, фармацевтическая композиция, способ лечения
AU751498B2 (en) 1997-04-11 2002-08-15 G.D. Searle & Co. flt3 ligand chimeric proteins
EP1115854A1 (en) 1998-09-25 2001-07-18 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
SG159381A1 (en) * 2001-10-10 2010-03-30 Novo Nordisk As Remodeling and glycoconjugation of peptides

Also Published As

Publication number Publication date
NO20031497D0 (no) 2003-04-02
AU8197098A (en) 1998-10-15
CA2711007C (en) 2012-10-02
EP1482046B1 (en) 2012-04-11
KR960700341A (ko) 1996-01-19
DE69425516T2 (de) 2001-06-13
NZ332188A (en) 2000-07-28
CA2153896A1 (en) 1994-08-04
AU697451B2 (en) 1998-10-08
US5790421A (en) 1998-08-04
CN1495197B (zh) 2013-01-16
PT1482046E (pt) 2012-06-06
ATE195552T1 (de) 2000-09-15
CN1970571A (zh) 2007-05-30
IL124112A (en) 2006-12-10
AU6095794A (en) 1994-08-15
IL125398A0 (en) 1999-03-12
EP0890640A2 (en) 1999-01-13
US20050260154A1 (en) 2005-11-24
EP0965638A3 (en) 2000-02-23
ES2422269T3 (es) 2013-09-10
PT2345724E (pt) 2013-08-22
EP0890640A3 (en) 1999-03-24
KR100375274B1 (ko) 2003-06-11
WO1994017185A1 (en) 1994-08-04
US6632426B2 (en) 2003-10-14
KR100390338B1 (ko) 2003-07-07
CN1495197A (zh) 2004-05-12
DK2345724T3 (da) 2013-09-30
HK1009288A1 (en) 1999-05-28
EP2345724B1 (en) 2013-07-03
GR3034745T3 (en) 2001-02-28
CA2711007A1 (en) 1994-08-04
IL124111A (en) 2002-09-12
JP2011207885A (ja) 2011-10-20
NZ314960A (en) 1999-01-28
US20030171559A1 (en) 2003-09-11
EP0974655A2 (en) 2000-01-26
NZ504840A (en) 2001-11-30
DK1482046T3 (da) 2012-06-25
CA2153896C (en) 1999-01-12
EP1482045A3 (en) 2004-12-29
NO952974D0 (no) 1995-07-27
CA2239360C (en) 2002-07-16
JPH08506018A (ja) 1996-07-02
DK0612846T3 (da) 2000-10-09
US5581476A (en) 1996-12-03
US6261550B1 (en) 2001-07-17
IL145994A (en) 2010-12-30
EP2345724A1 (en) 2011-07-20
EP1482046A3 (en) 2005-01-05
DE69425516D1 (de) 2000-09-21
US20010016191A1 (en) 2001-08-23
JP2006137762A (ja) 2006-06-01
CA2381489A1 (en) 1994-08-04
NO952974L (no) 1995-09-28
FI953593A0 (fi) 1995-07-27
EP1482045A2 (en) 2004-12-01
JP2010059170A (ja) 2010-03-18
LU92265I2 (fr) 2013-10-14
CN1970571B (zh) 2013-07-10
EP1233065A1 (en) 2002-08-21
CA2381489C (en) 2010-10-19
FI123078B (fi) 2012-10-31
NO20031497L (no) 2003-04-02
PT612846E (pt) 2001-01-31
US7381804B2 (en) 2008-06-03
NO20093489L (no) 1995-09-28
EP0612846A1 (en) 1994-08-31
FI953593A (fi) 1995-07-27
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
EP0974655A3 (en) 2001-10-24
CN1118572C (zh) 2003-08-20
NZ261765A (en) 1997-10-24
FI120769B (fi) 2010-02-26
JP2004113243A (ja) 2004-04-15
ES2150951T3 (es) 2000-12-16
ES2382927T3 (es) 2012-06-14
JP2006096762A (ja) 2006-04-13
IL108446A0 (en) 1994-04-12
CN1132527A (zh) 1996-10-02
ATE553199T1 (de) 2012-04-15
EP0965638A2 (en) 1999-12-22
IL108446A (en) 2003-01-12
IL145994A0 (en) 2002-07-25
EP0612846B1 (en) 2000-08-16
JP2009057368A (ja) 2009-03-19
EP1482046A2 (en) 2004-12-01
CA2239360A1 (en) 1994-08-04
HK1107356A1 (en) 2008-04-03
LV12642A (lv) 2001-04-20
FI20090384A (fi) 2009-10-21
US8058398B2 (en) 2011-11-15

Similar Documents

Publication Publication Date Title
HK1107356A1 (en) G-csf analog compositions and methods g-csf
IL110091A0 (en) Imidazo [4,5-c] pyridin-4-amines and pharmaceutical compositions containing them
EP0183350A3 (en) Dna endcoding human colony stimulating factor, peptide encoded thereby,vectors and transformed hosts containing such dna, and the production of all thereof
AU596997C (en) Pharmaceutical composition for the treatment of leukopenia
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ZA885101B (en) Human granulocyte macrophage colony stimulating factor and muteins thereof